PL4135840T3 - Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych - Google Patents
Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznychInfo
- Publication number
- PL4135840T3 PL4135840T3 PL21732998.6T PL21732998T PL4135840T3 PL 4135840 T3 PL4135840 T3 PL 4135840T3 PL 21732998 T PL21732998 T PL 21732998T PL 4135840 T3 PL4135840 T3 PL 4135840T3
- Authority
- PL
- Poland
- Prior art keywords
- soluble
- treatment
- amino acid
- water
- acid derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL433567A PL243119B1 (pl) | 2020-04-16 | 2020-04-16 | Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe nadające się do leczenia chorób o podłożu neurologicznym oraz zaburzeń psychiatrycznych |
| PCT/PL2021/050026 WO2021210997A1 (en) | 2020-04-16 | 2021-04-16 | Water-soluble, modified amino acid derivatives for treatment of neurological diseases, and selected psychiatric disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4135840T3 true PL4135840T3 (pl) | 2025-05-12 |
Family
ID=76483335
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL433567A PL243119B1 (pl) | 2020-04-16 | 2020-04-16 | Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe nadające się do leczenia chorób o podłożu neurologicznym oraz zaburzeń psychiatrycznych |
| PL21732998.6T PL4135840T3 (pl) | 2020-04-16 | 2021-04-16 | Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL433567A PL243119B1 (pl) | 2020-04-16 | 2020-04-16 | Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe nadające się do leczenia chorób o podłożu neurologicznym oraz zaburzeń psychiatrycznych |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230192608A1 (pl) |
| EP (2) | EP4527384A3 (pl) |
| CN (1) | CN115715219B (pl) |
| CA (1) | CA3175613A1 (pl) |
| ES (1) | ES3020435T3 (pl) |
| PL (2) | PL243119B1 (pl) |
| WO (1) | WO2021210997A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL240297B1 (pl) | 2019-04-16 | 2022-03-14 | Univ Jagiellonski | Modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych |
| PL450241A1 (pl) * | 2024-11-12 | 2026-05-18 | Uniwersytet Jagielloński | Pozytywny allosteryczny modulator (PAM) transportera EAAT2/GLT-1 glutaminianu do stosowania w leczeniu lub zapobieganiu świądu |
| WO2026150001A1 (en) | 2025-01-09 | 2026-07-16 | Iqure Pharma Inc. | Positive allosteric modulator (pam) of the eaat2/glt-1 glutamate transporter for use in the treatment or prevention of dravet syndrome |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW288010B (pl) * | 1992-03-05 | 1996-10-11 | Pfizer | |
| PL240297B1 (pl) | 2019-04-16 | 2022-03-14 | Univ Jagiellonski | Modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych |
-
2020
- 2020-04-16 PL PL433567A patent/PL243119B1/pl unknown
-
2021
- 2021-04-16 WO PCT/PL2021/050026 patent/WO2021210997A1/en not_active Ceased
- 2021-04-16 US US17/996,235 patent/US20230192608A1/en active Pending
- 2021-04-16 EP EP24215754.3A patent/EP4527384A3/en active Pending
- 2021-04-16 CN CN202180038326.1A patent/CN115715219B/zh active Active
- 2021-04-16 PL PL21732998.6T patent/PL4135840T3/pl unknown
- 2021-04-16 EP EP21732998.6A patent/EP4135840B1/en active Active
- 2021-04-16 ES ES21732998T patent/ES3020435T3/es active Active
- 2021-04-16 CA CA3175613A patent/CA3175613A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115715219B (zh) | 2026-01-06 |
| PL243119B1 (pl) | 2023-06-26 |
| EP4527384A3 (en) | 2025-07-02 |
| EP4135840A1 (en) | 2023-02-22 |
| PL433567A1 (pl) | 2021-10-18 |
| US20230192608A1 (en) | 2023-06-22 |
| WO2021210997A1 (en) | 2021-10-21 |
| CN115715219A (zh) | 2023-02-24 |
| ES3020435T3 (en) | 2025-05-22 |
| EP4135840B1 (en) | 2025-01-08 |
| CA3175613A1 (en) | 2021-10-21 |
| EP4527384A2 (en) | 2025-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE073599T2 (hu) | Módosított aminosav-származékok neurológiai betegségek és kiválasztott pszichiátriai rendellenességek kezelésére | |
| IL288214A (en) | Quinazolin-4-one derivatives are useful for the treatment of braf-related diseases and disorders | |
| ZA202212876B (en) | 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders | |
| EP4452331B8 (en) | Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders | |
| MY146238A (en) | Prodrugs of excitatory amino acids | |
| IL286636A (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OR DISORDERS RELATED TO KRAS | |
| WO2006023544A3 (en) | Therapeutic uses of inhibitors of rtp801 | |
| MX386258B (es) | Derivados de 5,7-dihidro-pirrolo-piridina para tratar enfermedades neurologicas y neurodegenerativas | |
| WO2007141796A3 (en) | Therapeutic uses of inhibitors of rtp801l | |
| WO2006058868A8 (de) | Substituierte pteridine zur behandlung von entzündlichen erkrankungen | |
| SG179410A1 (en) | Therapeutic uses of inhibitors of rtp801 | |
| MX373102B (es) | Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparación de tal compuesto y diferentes formas sólidas del mismo. | |
| EP4405355A4 (en) | LSD DERIVATIVES, SYNTHESIS AND METHOD FOR TREATING DISEASES AND DISORDERS | |
| PL1663244T3 (pl) | Pochodne pterydyny do leczenia chorób związanych z TNF-alfa | |
| MX2025002953A (es) | Derivados heteroaromaticos y aromaticos heterobiciclicos para el tratamiento de trastornos relacionados con ferroptosis | |
| WO2009058729A3 (en) | Thiazole carboxamide derivatives and their to treat cancer | |
| EP4527384A3 (en) | Water-soluble, modified amino acid derivatives for the treatment of neurological diseases and selected psychiatric disorders | |
| MX2020002630A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta. | |
| WO2016051306A3 (en) | Novel anthranilic acid derivatives | |
| WO2006021000A3 (en) | Substituted thienopyrrole carboxylic acid amides, pyrrolothiazole carboxylic acid amides, and related analogs as inhibitors of casein kinase i epsilon | |
| CA3264922A1 (en) | METHODS FOR THE TREATMENT OF DISEASES AND DISORDERS RELATED TO ANGPTL3 | |
| MX2020011453A (es) | Combinaciones para tratar el cancer. | |
| WO2002055481A8 (en) | Prodrugs of excitatory amino acids | |
| IL147953A0 (en) | Derivatives and pharmaceutical compositions of n-hydroxymethyl tetramethylcyclopropyl-carboxamide, having anti-epileptic, neurological, and cns activity, and method for their preparation | |
| AU2021337864A9 (en) | Cellular composition for treatment of diseases, disorders or conditions and method of use |